The FDA’s green light for Lupin’s Phytonadione Injectable Emulsion USP signals a new revenue stream that could tap into the $52.3 m annual sales of the reference drug in the U.S. market, per IQVIA MAT data.
Shares of Lupin closed at ₹1,947 on October 8, down 3.27% amid a broader sell‑off in the pharma sector after a string of mixed earnings reports. The drop follows the company’s announcement of the FDA approval, which may have raised expectations for a higher valuation.
Lupin also secured approval for its ANDA for Sodium Zirconium Cyclosilicate, a treatment for hyperkalemia, just weeks earlier. That product’s launch adds a second potential revenue source, though its market size is still being priced by analysts.
Analysts on the NSE note that the FDA clearances could boost Lupin’s earnings by 8–10% if the company ramps up production and exports quickly. However, the company has yet to provide guidance on how much of the $52.3 m market it expects to capture, leaving investors to speculate.
Lupin’s next earnings report is slated for November 15, when the company will disclose its Q2 revenue and profit figures. Investors will be looking for a concrete forecast on how the new approvals translate into top‑line growth and whether the company plans to invest in U.S. manufacturing capacity.
In the meantime, the stock’s volatility underscores a market sentiment that favors companies with proven revenue streams over those with pending regulatory approvals. The FDA nod is a positive signal, but the price action shows that traders are waiting for clearer financial impact before committing more capital.